Status:
COMPLETED
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
Lead Sponsor:
Solvay Pharmaceuticals
Collaborating Sponsors:
H. Lundbeck A/S
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study ...
Eligibility Criteria
Inclusion
- Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder
- Body weight of 100-250 lbs
- Male or females
- 18-55 years of age
Exclusion
- Subjects who are acutely psychotic
- Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00139906
Start Date
August 1 2005
End Date
October 1 2006
Last Update
January 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 1
National City, California, United States